Sep 26, 2026
Cambridge biotech co-founded by Alnylam founder Maraganore files for IPO
City Therapeutics, an RNAi biotech co-founded by Alnylam founder Maraganore, has filed for an initial public offering (IPO) on Nasdaq under the ticker CTY. The company, which has raised approximately $238.8 million since its launch in October 2024, currently employs 81 people and has established partnerships with Bausch + Lomb and Biogen. The IPO aims to build on the success of Alnylam Pharmaceuticals Inc.
Company relevance
88.80%
Company sentiment
Somewhat-Bullish
Overall sentiment
Neutral
Sep 20, 2026
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
Alnylam Pharmaceuticals has updated its 2026 TTR franchise revenue outlook to $4.2 billion–$4.5 billion, reflecting a shift in market mix towards 80% first-line and 20% second-line use for AMVUTTRA. Despite the revision, the company emphasizes strong market fundamentals with many undiagnosed patients and upcoming pipeline catalysts in Huntington's disease, obesity, and bleeding disorders. Alnylam also noted that AMVUTTRA's deep TTR knockdown and quarterly dosing contribute to its market momentum.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish